Short answer
TriSalus Life Sciences, Inc. (TLSI) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $9M (down 2.9% year over year) with net income of $2M.
Q1 2026 key financials · XBRL
- Revenue
- $9M
- −2.9% YoY
- Net income
- $2M
- +114.8% YoY
- Operating margin
- -94.5%
- Gross margin
- 86.2%
- EPS (diluted)
- $0.03
- +107.7% YoY
Source: XBRL data from the TriSalus Life Sciences, Inc. (TLSI) Q1 2026 10-Q on SEC EDGAR. USD.
TriSalus Life Sciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $8.9M, down 2.9% YoY from $9.2M, primarily reflecting commercial expansion
- Gross margin 86.2% vs 83.7% YoY; operating loss $8.4M vs $7.3M
- TriNav product portfolio sole commercial line; revenue $8.9M, down 2.9% YoY
- Cash $56.6M vs $20.4M at December 31, 2025; operating cash use $6.5M vs $4.5M
- Financing provided $42.4M, including $42.6M public-offering proceeds; continued capital needs and reimbursement risks ahead
Risk Factors
- No material risk-factor changes disclosed from the December 31, 2025 Form 10-K
- Credit Agreement fourth amendment filed, indicating updated financing terms
- Amended and Restated Insider Trading Policy filed, reflecting compliance-policy changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TriSalus Life Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.